Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Week 28 12 juli t/m 16 juli 2010
Volgen
Hearts23 schreef:
Totaal onbegrijpelijke reactie maar dat zal wel aan mijn beperkte bevattingsvermogen liggen.
Wie bedoel je met "het clubje " ?
Mijn zwarte aangevers-lijstje ga ik natuurlijk niet met naam en toenaam op dit forum vermelden. Degenen die het betreft, weten het zelf maar al te goed, en aan de hand van wat combineren en deduceren is het voor iedere forumgenoot vrij eenvoudig te achterhalen, wie de monddood-makers zijn. Vrijheid van meningsuiting: ook in dit land voor sommigen wat meer, (en dus) voor anderen wat minder tot en met volledige liquidatie van meningsuiting. Een slechte zaak voor iedere serieuze Crucellwatcher: juist wat onwelgevallig overkomt houdt de belegger met beide benen op de o zo belangrijke grond. Het aantal facetten van 'de waarheid' is met deze ban tot onaanvaardbaar peil gedaald, althans voor een ieder, die zich serieus met dit aandeel bezighoudt. Schande, dat je je voor censuur laat misbruiken, IEX!
oudje schreef:
Ach Hearts, Wim Kan zong het meer dan 30 jaar geleden al:
NEE NEE NEE, NAMEN NOEMEN WE NIET.
Overigens vergeet de schrijver dat wij in Nederland allemaal onze vrijheid hebben. En dat uit zich in een volkomen vrijheid van keuze van je beleggingen.
Ron B is in ieder geval de vrijheid van meningsuiting ontnomen... Heel vaak zijn het juist diegenen die zo hoog opgeven over 'vrijheid', die anderen diezelfde vrijheid (willen) ontnemen: de wereldgeschiedenis staat bol van de voorbeelden, van fascist tot en met communist, en alles wat zich daartussen bevindt.
Eden Biodesign Assists Momotaro-Gene, Inc. to Commence Human Clinical Trials Less Than 12 Months After Being Engaged to Produce a Recombinant Adenovirus Vector from a New Cell Line Wednesday, Jul. 14, 2010 Eden Biodesign Ltd. and Momotaro-Gene, Inc. today announced the success of a collaborative global project that demonstrated Eden’s capabilities to work quickly to develop an adenoviral manufacturing process providing Momotaro-Gene with drug substance and vialed drug product ready for their clinical trial within 12 months. Momotaro-Gene, Inc. already cleared its first IND (Investigational New Drug) application with this drug product to the FDA and expects to start its First-In-Man clinical trial at Mt. Sinai Hospital, USA, this month. By accessing Eden Biodesign’s expertise as a global provider of outsourced cGMP manufacturing, and through the application of Crucell’s proprietary technology, Momotaro-Gene was able to employ a PER.C6® human cell line to manufacture a recombinant adenoviral vector which is unlikely to replicate in a normal human cell line. As a result, with Eden Biodesign’s guidance, Momotaro-Gene achieved a product suitable for global regulatory approval for Phase I trials. Momotaro-Gene led by Prof. Hiromi Kumon at the Okayama University developed the next generation therapeutic cancer vaccine which will help treat prostate cancer patients in Japan and the United States. “Eden Biodesign’s involvement with Momotaro-Gene was a very fortunate alignment of knowledge, rare skills and technology,” said Dr. Crawford Brown, CEO, Eden Biodesign. “We were able to dramatically advance a project that had encountered challenges which Eden Biodesign was uniquely qualified to overcome. The team has been involved in this area for a number of years and we are excited to be working with customers in the emerging field of therapeutic vaccines and proud to contribute to product and process design.” “We engaged Eden Biodesign because they were previously known to us from their consultancy activities in Japan and particularly due to their ability to tackle the most-difficult biodesign challenges,” said Momotaro-Gene’s CEO, Mr. Hitoshi Shiomi. “The success of our most-recent engagement is the product of the very deliberate application of world-class talent, and we couldn’t be happier with the outcome. Eden assisted not only to supply clinical product but support our Japanese and USA regulatory approvals.” As well as having an established track record and engagement over the last 10 years with several Japanese companies, providing support and training to overcome technical challenges, Eden Biodesign is able to demonstrate through the work with Momotaro-Gene, Inc. that the company is much more than a CMO in providing regulatory support as part of their drug development team.tinyurl.com/2up3ntz
josti5 schreef:
Mijn zwarte aangevers-lijstje ...
www.cbpweb.nl/Pages/home.aspx
flosz schreef:
Eden Biodesign Assists Momotaro-Gene, Inc. to Commence Human Clinical Trials Less Than 12 Months After Being Engaged to Produce a Recombinant Adenovirus Vector from a New Cell Line
...
www.crucell.com/Partners%20-%20Genera... Gene Therapy Momotaro-Gene Inc. Aug. 2009 PER.C6® Prostate cancer phase I Dus binnen een jaar na de licentie al in phase I. Uitzonderlijk snel. De uitzondering op de regel.
maxen schreef:
[quote=flosz]
Eden Biodesign Assists Momotaro-Gene, Inc. to Commence Human Clinical Trials Less Than 12 Months After Being Engaged to Produce a Recombinant Adenovirus Vector from a New Cell Line
...
[/quote]
www.crucell.com/Partners%20-%20Genera... Gene Therapy
Momotaro-Gene Inc.
Aug. 2009
PER.C6®
Prostate cancer
phase I
Dus binnen een jaar na de licentie al in phase I. Uitzonderlijk snel. De uitzondering op de regel.
En meteen weer de koers pumpen!! ;)
josti5 schreef:
de vrijheid van meningsuiting ontnomen...
Via een link op pagina 1 is zijn mailadres te vinden...bv om gezellig samen de Universele Verklaring van de Rechten van de mens te bespreken. ( www.ohchr.org/EN/UDHR/Documents/UDHR_... ) Maar pas op: over een jaar of twee/drie niet hier komen klagen over terreur/bedreigingen/telefonische belaging/lasterlijke leugens etc., ook niet als er serieuze pers. beveiliging aan te pas moet komen! En ach, lijstjes zijn steeds te herzien, een fin.int. syndicaatje meer of minder:BOEiend! "And the man with the golden gun thinks he knows so much”(T. Amos).
josti5 schreef:
Ron B is in ieder geval de vrijheid van meningsuiting ontnomen...
Zijn mening was niet het probleem. Maar het Spammen wel denk ik.
josti5 schreef:
[quote=oudje]
Ach Hearts, Wim Kan zong het meer dan 30 jaar geleden al:
NEE NEE NEE, NAMEN NOEMEN WE NIET.
Overigens vergeet de schrijver dat wij in Nederland allemaal onze vrijheid hebben. En dat uit zich in een volkomen vrijheid van keuze van je beleggingen.
[/quote]
Ron B is in ieder geval de vrijheid van meningsuiting ontnomen...
Heel vaak zijn het juist diegenen die zo hoog opgeven over 'vrijheid', die anderen diezelfde vrijheid (willen) ontnemen: de wereldgeschiedenis staat bol van de voorbeelden, van fascist tot en met communist, en alles wat zich daartussen bevindt.
En nog vaker maken personen misbruik van de diezelfde vrijheid van meningsuiting!!!!! De wereldgeschiedenis staat bol van de voorbeelden: de rascist, de milieuactivist, Ron B. enz enz. De goeden lijden altijd onder de kwaden.
….. OctoPlus is sindsdien klein maar solide, zeggen marktvolgers. En het sluit deals. Maandag werd een contract getekend dat 'een bijdrage van betekenis vormt aan de jaarlijkse omzet'. Het is de derde deal in amper twee weken, nadat eind juni een overeenkomst was gesloten met farmabedrijf Novartis. Daarmee heeft OctoPlus nog één probleem: het is te onbekend. 'If you don't have the cash flow than have the news flow', is een Engelse beurswijsheid. Dat heeft het bedrijf onvoldoende. Sinds het genoteerd is, heeft OctoPlus 83 persberichten uitgegeven. In dezelfde tijd verstuurde Galapagos 139 persberichten. Crucell verstuurde er 159. www.fd.nl/artikel/17398560/boven-mark...
Two-step vaccine may offer "universal" flu jab (The vaccine, which uses DNA from Netherlands-based Crucell NV, "looks pretty safe," Fauci said. "They are already well into, at least a full year into, a Phase 1 trial.") A two-step flu vaccine using DNA to "prime" the immune system and then a traditional seasonal influenza vaccine may be able to protect against all strains of the virus -- providing a long-sought "universal" flu vaccine, U.S. researchers said on Thursday. The team at the National Institute of Allergy and Infectious Diseases is already testing the new vaccine in people and says the results of tests in mice, ferrets and monkeys suggest the industry may finally be able to dump the cumbersome process of making fresh flu vaccines every year. "This is the first step, conceptually, toward a good shot at a universal vaccine," NIAID Director Dr. Anthony Fauci said in a telephone interview. Every year, the influenza strains that are circulating mutate a little bit and at any given time several very different strains are infecting people. In some years a new mutant pops up -- such as the new H1N1 swine flu strain that appeared in March 2009 to spark a pandemic. Vaccine makers have to change their formulations every year to match the current strains. To make matters worse, virtually all flu vaccines are made using decades-old technology based on chicken eggs that is both slow and prone to contamination. So the goal is to come up with a universal influenza vaccine that could protect people from all flu strains for decades or even for life. NIAID's Dr. Gary Nabel said his lab has taken a big step toward this goal. Their method, described in the journal Science, starts with a piece of DNA based on the hemagglutinin protein -- a mushroom-shaped structure on the outside of the virus that gives flu strains the "H" in their names. The DNA directs the body to make antibodies against a part of the flu virus that is normally hidden -- on the "stem" of the hemagglutinin protein. This part is conserved, meaning it does not change from flu strain to flu strain. OLD AND NEW STRAINS Vaccinated mice and ferrets produced antibodies that protected them against flu strains from 1934 through 2007. "We are excited by these results," Nabel said. "The prime-boost approach opens a new door to vaccinations for influenza that would be similar to vaccination against such diseases as hepatitis, where we vaccinate early in life and then boost immunity through occasional, additional inoculations in adulthood." The vaccine, which uses DNA from Netherlands-based Crucell NV, "looks pretty safe," Fauci said. "They are already well into, at least a full year into, a Phase 1 trial." Such trials are meant to see if a new drug or vaccine is safe in people. A larger, Phase 2 trial could start next year, Fauci said. Seasonal influenza kills 250,000 to 500,000 people a year globally, including 36,000 in the United States. Pandemics often kill more and while H1N1 has not been especially deadly, it has killed far more children, young adults and pregnant women than seasonal flu usually does. The experimental vaccine protected animals against H5N1 bird flu, as well. While avian influenza only rarely infects people, it has killed 296 of the 500 sickened by it since 2003. Flu experts fear H5N1 could mutate and cause a pandemic far worse than swine flu and, using current vaccine technology, it will take months to formulate a good vaccine against it. Swine flu made its spread global within six weeks. www.reuters.com/article/idUSTRE66E7BM... NIH Scientists Advance Universal Flu Vaccinewww.niaid.nih.gov/news/newsreleases/2... www.sciencemag.org/cgi/content/abstra...
flosz schreef:
Universele Verklaring van de Rechten van de mens
www.ohchr.org/EN/UDHR/Documents/UDHR_... )
Ter aanvulling. The UN Declares Access to Water and Sanitation a Human Rightwww.un.org/News/Press/docs/2010/ga109...
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
900,06
0,00%
EUR/USD
1,0740
-0,15%
FTSE 100
8.313,67
+1,22%
Germany40^
18.444,40
+0,08%
Gold spot
2.319,34
+0,23%
NY-Nasdaq Composite
16.332,56
-0,10%
Stijgers
Dalers